The best way to know your true omega-3 status is not to count how many times a week you eat salmon, but to , which quantifies the amount of EPA plus DHA as a percentage of total fatty acids in red blood cell membranes; this measurement is more stable and more representative of long-term intake than plasma concentrations, which fluctuate from day to day, and .
For most Western adults to raise their Omega-3 Index from the typical 4 percent to the recommended 8 percent, researchers estimate that combined are needed, an amount far greater than what most people get from their usual diet, and one that puts into perspective the gap between official recommendations and what science actually suggests as optimal.
⏱ 2 min read | Tags: Omega-3
The Omega-3 Index, a biomarker developed by doctors Bill Harris and Clemens von Schacky, measures the amount of EPA plus DHA as a percentage of total fatty acids in red blood cell membranes, and was originally proposed as a new risk factor for death from coronary heart disease; since its creation in 2004, the Omega-3 Index has been evaluated in numerous populations and shows strong correlations with multiple health indicators that go far beyond heart function.
The most relevant findings include: a higher Omega-3 Index was associated with ; higher Omega-3 Index scores correlate with in multiple areas of the brain and greater executive function; lower scores correlate with a wider distribution of red blood cell volume, an indicator of nutritional deficiency or disease; and COVID-19 patients with indexes of 5.7% or higher were 75% less likely to die of the disease compared with those who had the lowest indexes.
Measuring omega-3 concentrations in red blood cells than plasma or serum measurements, which fluctuate daily; most people in the United States and other Western countries have an Omega-3 Index of about 4%, but robust evidence suggests that an index of 8-11% provides the greatest health benefits, and to raise an index from 4% to the recommended range of 8% or higher, intake should be between 1,750 and 2,500 mg per day of EPA+DHA.
. For general maintenance, ~1 g/day. With food (improves absorption and reduces the aftertaste).
At a high dose (2-4 g/day EPA+DHA) it .
View the study (meta-analysis) →Higher blood levels of EPA+DHA are associated with (meta-analysis of 17 cohorts with ≈42,000 people, FORCE Consortium, Nat Commun 2021).
View the study (meta-analysis) →In adults ≥60 years, >2 g/day (≈ +330 g) and improves functional mobility (10 RCTs, >550 people).
View the study (systematic review) →; explains part of its cardiovascular and brain effects.
View the study (systematic review) →5 trials · 300 participants: . In endometriosis specifically, it did NOT reduce pelvic pain in 1 trial (Grade D).
View the study (Grade B) →Modest effect on cognition; DHA in phospholipid form (roe, krill) via Mfsd2a, useful mainly in APOE4 carriers.
View the study (clinical trial) →At a low dose (1 g/day) it .
See the study (large RCT (VITAL)) →1 trial · 69 participants: omega-3 did NOT reduce endometriosis-associated pelvic pain compared with placebo.
See the study (Grade D) →⏱ 7 min read
Omega-3 fatty acids are polyunsaturated fats that play critical roles in human biology, taking part in a wide range of biochemical pathways and throughout life; the main ones are plant-derived alpha-linolenic acid and marine-derived EPA and DHA, and it is on these last two that most of the clinical evidence relevant to human health rests.
Half a century of research has revealed that omega-3s take part in almost every aspect of human physiology: they , prevent age-related macular degeneration, reduce DNA damage and oxidative stress, preserve muscle mass in older adults, influence infant brain development, improve night vision, reduce premature births, and show promising effects in improving clinical outcomes in severe viral infections.
In a study that followed more than 42,000 people from 17 prospective cohorts, blood concentrations of omega-3s were inversely associated with the risk of death from all causes: those with the highest levels of EPA, DHA, and docosapentaenoic acid were 15 to 18 percent less likely to die prematurely than those with the lowest levels, with no significant association for plant-derived ALA.
Another study of 2,240 people in their mid-sixties showed something especially striking: ; nonsmokers with high omega-3 had an 85 percent survival rate, whereas nonsmokers with low omega-3 and smokers with high omega-3 had exactly the same rate of 71 percent, which positions omega-3 as a longevity risk factor comparable to smoking.
Beyond its specific effects, omega-3 status behaves as a : in the FORCE consortium, with more than 42,000 people from 17 cohorts, those with the highest blood levels of EPA, DHA, and docosapentaenoic acid showed , with parallel reductions in cardiovascular, cancer, and other-cause mortality; for that reason an and a value below 4 percent as a high-risk marker.
The problem is that this deficit is the norm, not the exception. The world omega-3 map updated in 2024 (342,864 people from 48 countries) found that , with the lowest values in places such as Iran, Egypt, India, and Brazil, versus the highest in Japan, South Korea, Iceland, and Norway. In other words: a good part of the Western population lives chronically below the range associated with the greatest benefits.
And that deficit has a measurable cost in lives. The analysis of preventable causes of death by Danaei and colleagues estimated that low intake of marine omega-3s contributed to (up to nearly 96,000 at the upper limit of the interval), placing it among the leading dietary factors of avoidable mortality, ahead of much more widely publicized risks. Correcting that deficit —bringing the Omega-3 Index closer to the 8 to 11 percent range— is one of the nutritional interventions with the greatest preventive potential at the population level.
The most robust clinical trials on omega-3s and cardiovascular health show heterogeneous results that are explained in part by differences in design, dose, formulation, and population characteristics; the REDUCE-IT trial, with more than 8,000 participants at high cardiovascular risk taking 4 grams daily of pure EPA for five years, found a 25 percent reduction in the rate of ischemic events including cardiovascular death, a result that places it among the most relevant in preventive cardiology of the last decade.
A comprehensive analysis of 40 clinical trials found that fish oil supplementation is associated with , 13 percent fewer heart attacks overall, and 9 percent lower mortality from coronary heart disease, with dose-dependent effects: every additional 1,000 milligrams of EPA plus DHA per day reduces the risk of cardiovascular events by an additional 5.8 percent and the risk of heart attack by an additional 9 percent.
One of the lesser-known benefits of omega-3s is their ability to preserve and increase muscle mass through well-documented anticatabolic and anabolic effects: they , improve muscle protein synthesis by enhancing the muscle's response to insulin and amino acids, and when combined with resistance training in older adults, they produce greater gains in strength and functional performance than training alone.
A systematic review of ten randomized controlled trials with more than 550 adults aged 60 or older found that omega-3 supplementation and improved functional mobility, with greater effects in those who consumed more than 2 grams per day, which makes omega-3s a first-line tool in the prevention of sarcopenia, the progressive loss of muscle mass that is one of the main causes of functional dependence in old age.
, which gives an idea of the fundamental structural role this fatty acid plays in the architecture and function of the central nervous system; its importance begins in the womb, where the concentration of DHA in breast milk is strongly influenced by the mother's diet and determines aspects of the infant's mental and psychomotor development that can be measured in later years of childhood.
For people who carry the APOE4 gene, the main genetic risk factor for Alzheimer's, there is an important particularity that few science communicators mention: they fish oil supplements, probably because fish contains DHA in the form of phospholipids and common supplements offer it as triglycerides or ethyl esters, and that difference determines how DHA is transported to the brain across the blood-brain barrier.
Multiple studies have investigated the effects of omega-3s on depression, the most common mood disorder in the world, with results that point consistently in the same direction: a double-blind trial with more than 430 patients found that omega-3 supplementation produced improvements in depressive symptoms comparable to those seen with common antidepressants, especially in those who did not have associated anxiety disorders.
A meta-analysis of 20 studies with more than 5,800 participants confirmed that , especially in longer treatments with patients with mild to moderate depression, and noted that ; the mechanisms that explain this effect include the anti-inflammatory properties of omega-3s and their ability to influence neuroendocrine function, including the production and sensitivity of key neurotransmitters.
Omega-3s are available in three main forms: triglycerides, which is the natural form and which many consider to have higher bioavailability; phospholipids, which some researchers believe have the highest absorption but which tend to offer lower concentrations or poorer value for money on the market; and ethyl esters, which are the result of molecular distillation and are found in the main pharmaceutical preparations such as Lovaza and Vascepa, with somewhat lower bioavailability if not taken with a fatty meal.
in the supplement industry: oxidized products not only lose efficacy but may have counterproductive effects, which makes product quality, storage conditions, and manufacturing date factors as relevant as the dose or the chemical form, aspects that rarely appear in the advertising of most brands on the market.
Information, not medical advice. Scientific evidence reflects the quality of the studies.